Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout

Volume: 22, Issue: 11, Pages: 1397 - 1406
Published: Apr 30, 2021
Abstract
Gout is an inflammatory disease triggered by deposition of urate crystals secondary to longstanding hyperuricemia, and its management implies both the treatment of flares and management of hyperuricemia. Dotinurad is a selective urate reabsorption inhibitor (SURI), potently inhibits urate transporter 1 in the apical surface of renal proximal tubular cells, and has been approved for the treatment of gout and hyperuricemia in Japan.This overview...
Paper Details
Title
Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout
Published Date
Apr 30, 2021
Volume
22
Issue
11
Pages
1397 - 1406
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.